Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
SPSpero Therapeutics, Inc. logo

Spero Therapeutics, Inc. (SPRO)

NASDAQ Global Select · Currency in USD
$1.11 ▼ -0.02 (-1.77%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.10 ▼ -0.01 (-0.90%)
After hours: Oct 23, 7:58 PM ET

Summary

Previous Close
$1.13
Open
$1.13
Day's Range
$1.10 – $1.13
52 Week Range
$1.08 – $3.08
Volume
316,181
Avg. Volume
1,277,993
Market Cap
$64.64M
Beta (5Y Monthly)
1.50
PE Ratio (TTM)
7.93
EPS (TTM)
$0.13
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
$0.06 (5.41%)
Ex-Dividend Date
Sep 16, 2015
1y Target Est
--

Profile: Spero Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
25
CEO
Esther Rajavelu

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.14
DateEst.Actual
Aug 12, 2026-$0.17-$0.16Beat
May 13, 2026-$0.18-$0.13Beat
Mar 26, 2026-$0.20$0.53Beat
Nov 13, 2025-$0.25-$0.13Beat
Aug 12, 2025-$0.38-$0.03Beat
May 13, 2025-$0.55-$0.25Beat

Analyst view

Rating: Buy
Buy 46% · Hold 38% · Sell 15%

Get free alerts on SPRO and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.